$SYK

Fletcher Robert S sold $37K of SYK

Fletcher Robert S (VP, Chief Legal Officer) sold 120 shares of STRYKER CORP (SYK) at $304.22 on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fletcher Robert S
Published May 29, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SYK
Neutral
medium confidence
Mentioned
$SYK
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYKNeutralLow
01

Why it matters

This provides incremental sentiment context but no fundamental update; traders may treat it as routine unless paired with other negative catalysts.

02

Market read

Routine 10b5-1 insider selling disclosure; expected to have limited impact on valuation absent corroborating fundamental news.

03

What to watch

The filing does not reveal whether other insiders/funds are buying or selling, nor does it provide any new operational or financial information.

Relevance 6/10Novelty 3/10Timing: Filed 2026-05-29; reflects sale executed 2026-05-28.

Background

The article is an SEC Form 4 insider transaction disclosure for Stryker (SYK), indicating an officer sale executed under a Rule 10b5-1 pre-arranged plan.

Company-level read

Ticker impact

$SYKNeutralMedium confidence
Context

SEC Form 4 shows SYK officer Fletcher Robert S sold 120 shares in an open-market transaction on 2026-05-28 under a 10b5-1 plan.

Expected impact

Limited, likely sentiment-only; no clear directional catalyst from this filing alone.

Evidence & confidence

The filing is an ownership-change disclosure (not earnings/M&A/regulatory) and explicitly indicates a pre-arranged 10b5-1 plan, which reduces interpretive value versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no sector-wide catalyst described.

None indicated.

None indicated.

Counterpoint

Because the sale is small relative to typical institutional float, the market may overreact to headlines; the 10b5-1 label suggests mechanical execution rather than a view on SYK.

Key entities

  • Stryker Corp

    Company whose insider transaction was disclosed via SEC Form 4.

  • Fletcher Robert S

    VP, Chief Legal Officer who sold 120 shares of SYK under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SYKHighAI 8/10

Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS

Stryker (SYK) shares fell $26.70 (-8.8%) on Sept. 8, 2026, after its CFO revealed persisting manufacturing issues in its Peripheral Vascular unit, acquired from Inari Medical. The firm Hagens Berman is investigating potential disclosure violations. The issue, initially thought resolved, led to lost sales and backorders, with the CFO stating it will continue into Q4.

$SYKLow

Why Stryker (SYK) Stock Is Down Today

Stryker (SYK) shares fell 6.9% after management at a healthcare conference indicated longer-than-expected supply chain issues and slower joint replacement recovery, potentially affecting revenue. The company had reported solid Q2 results in July. Insider sales and mixed hedge fund activity were also noted.

$SYKMed

Stryker stock drops 7.7% as supply problems and weak joint replacement sales hit outlook

Stryker shares dropped 7.7% on Tuesday due to ongoing supply chain issues and weaker-than-expected joint replacement sales. CFO Preston Wells stated that manufacturing problems will persist into Q4, impacting sales growth. The company also missed recovery expectations in its joint replacement business, citing seasonal weakness. Investors are concerned about the timing of a broader recovery.